Cutera (NASDAQ:CUTR) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Cutera (NASDAQ:CUTR) in a research report report published on Friday. The brokerage issued a sell rating on the medical device company’s stock.

Cutera Stock Up 3.9 %

CUTR opened at $0.36 on Friday. Cutera has a twelve month low of $0.28 and a twelve month high of $4.97. The company has a fifty day moving average of $0.47 and a 200-day moving average of $0.91. The stock has a market cap of $7.34 million, a PE ratio of -0.06 and a beta of 1.26.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of CUTR. Ground Swell Capital LLC bought a new stake in shares of Cutera in the 2nd quarter worth $37,000. Bank of Montreal Can grew its position in Cutera by 14.2% in the 2nd quarter. Bank of Montreal Can now owns 282,704 shares of the medical device company’s stock worth $455,000 after purchasing an additional 35,248 shares in the last quarter. Finally, Squarepoint Ops LLC increased its stake in Cutera by 164.5% in the 2nd quarter. Squarepoint Ops LLC now owns 113,964 shares of the medical device company’s stock valued at $172,000 after buying an additional 70,870 shares during the last quarter. Institutional investors and hedge funds own 90.70% of the company’s stock.

About Cutera

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform.